STOCK TITAN

Tyra Biosciences CEO gets 864-share stock grant

Tyra Biosciences’ President and CEO received a small equity grant under the 2021 Employee Stock Purchase Plan, modestly increasing his direct shareholdings.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tyra Biosciences, Inc. (TYRA) reported that President and CEO Todd Harris acquired common stock through an equity plan. On September 15, 2026, he received 864 shares of common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan. Following this grant, he directly holds 1,438,495 shares of common stock, which include restricted stock units. No transactions are reported under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Harris Todd
Role President and CEO
Type Security Shares Price Value
Grant/Award Common Stock F1, F2 864 $9.129 $8K
Holdings After Transaction: Common Stock — 1,438,495 shares (Direct)
Footnotes (2)
  1. F1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
  2. F2. Includes restricted stock units.
Shares acquired 864 shares Grant of common stock to Todd Harris on September 15, 2026
Grant price per share $9.129 per share Value attributed to the 864-share grant on September 15, 2026
Shares owned after transaction 1,438,495 shares Direct common stock holdings of Todd Harris after the grant, including restricted stock units
Employee Stock Purchase Plan financial
"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
restricted stock units financial
"Includes restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TYRA report for President and CEO Todd Harris?

Todd Harris received 864 shares of Tyra Biosciences common stock on September 15, 2026 as a grant or award under the company’s 2021 Employee Stock Purchase Plan, increasing his direct holdings.

At what price were the new TYRA shares attributed to Todd Harris?

The 864 shares of Tyra Biosciences common stock granted to Todd Harris were attributed a value of $9.129 per share in the filing related to the 2021 Employee Stock Purchase Plan.

How many TYRA shares does Todd Harris own after this Form 4 transaction?

After the reported grant, Todd Harris directly owns 1,438,495 shares of Tyra Biosciences common stock. This total includes restricted stock units as disclosed in the footnotes.

Was the TYRA insider transaction by Todd Harris made under a Rule 10b5-1 plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the transaction was made under a Rule 10b5-1 trading plan.

What plan was used for Todd Harris’s latest TYRA share acquisition?

The filing states that the 864 shares of Tyra Biosciences common stock were acquired under the company’s 2021 Employee Stock Purchase Plan, reflecting participation in an employee equity purchase program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harris Todd

(Last)(First)(Middle)
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET

(Street)
CARLSBAD CALIFORNIA 92008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/15/2026A(1)V864A$9.1291,438,495(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
2. Includes restricted stock units.
/s/ Ali D. Fawaz, Attorney-in-Fact09/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading